Jinal Bhiman to HIV Infections
This is a "connection" page, showing publications Jinal Bhiman has written about HIV Infections.
Connection Strength
0,901
-
Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System. Curr HIV/AIDS Rep. 2017 04; 14(2):54-62.
Score: 0,155
-
Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med. 2015 Nov; 21(11):1332-6.
Score: 0,140
-
Rapid intra-host diversification and evolution of SARS-CoV-2 in advanced HIV infection. Nat Commun. 2024 Aug 22; 15(1):7240.
Score: 0,065
-
SARS-CoV-2 humoral immunity in people living with HIV-1. Trends Immunol. 2024 Jul; 45(7):511-522.
Score: 0,064
-
Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 From Adult Index Cases With and Without Human Immunodeficiency Virus in South Africa, 2020-2021: A Case-Ascertained, Prospective, Observational Household Transmission Study. Clin Infect Dis. 2023 02 08; 76(3):e71-e81.
Score: 0,058
-
High prevalence of SARS-CoV-2 antibodies in pregnant women after the second wave of infections in the inner-city of Johannesburg, Gauteng Province, South Africa. Int J Infect Dis. 2022 Dec; 125:241-249.
Score: 0,057
-
SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21. Lancet Infect Dis. 2022 Jun; 22(6):821-834.
Score: 0,055
-
V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. Cell Rep. 2018 12 11; 25(11):3123-3135.e6.
Score: 0,044
-
HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. Cell Host Microbe. 2018 10 10; 24(4):593-599.e3.
Score: 0,043
-
Strategies for a multi-stage neutralizing antibody-based HIV vaccine. Curr Opin Immunol. 2018 08; 53:143-151.
Score: 0,042
-
Size Doesn't Matter: Shorter Antibody Loops Can Infiltrate HIV's Env Apex Defenses. Immunity. 2017 05 16; 46(5):762-764.
Score: 0,039
-
New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. J Virol. 2016 01 01; 90(1):76-91.
Score: 0,035
-
Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 2013 Oct; 9(10):e1003738.
Score: 0,031
-
Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Sci Rep. 2022 02 15; 12(1):2552.
Score: 0,014
-
Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. Nat Commun. 2021 08 10; 12(1):4817.
Score: 0,013
-
Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications. Sci Rep. 2020 04 10; 10(1):6201.
Score: 0,012
-
Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage. PLoS Pathog. 2019 09; 15(9):e1008005.
Score: 0,011
-
Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog. 2017 01; 13(1):e1006074.
Score: 0,010
-
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014 May 01; 509(7498):55-62.
Score: 0,008
-
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012 Nov; 18(11):1688-92.
Score: 0,007